Thursday, May 19, 2022

    Sales of Sanofi-Aventis blockbuster drug Plavix rebound in US – report

    PARIS (AFX) – US sales of the Sanofi-Aventis anti-blood clot drug Plavix have rebounded to exceed sales of a generic competitor made by Apotex as supplies of the generic drug fall amid a court injunction against it, the daily Les Echos said, citing data from a US industry monitoring firm relayed by Societe Generale.

    The injunction last year allowed supplies of the Apotex drug that had already been shipped to stay on the market, but blocked further sales pending a hearing that is due to start Jan 22.

    Plavix has been one of Sanofi-Aventis’ blockbuster drugs. Its US sales fell sharply after the generic version was put on the market in the middle of last year.



    Copyright AFX News Limited 2006. All rights reserved.

    The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.

    AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited

    Recent Articles

    Related Stories